Head-To-Head Review: Palvella Therapeutics (NASDAQ:PVLA) and Insmed (NASDAQ:INSM)

Insmed (NASDAQ:INSM) and Palvella Therapeutics (NASDAQ:PVLA) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, profitability, institutional ownership and valuation.

Earnings & Valuation

This table compares Insmed and Palvella Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insmed	$606.42 million	46.58	-$1.28 billion	($4.11)	-31.47
Palvella Therapeutics	$42.81 million	51.02	-$41.72 million	($4.83)	-31.38

Palvella Therapeutics has lower revenue, but higher earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Palvella Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Insmed has a beta of 0.82, suggesting that its stock price is 18% less volatile than the S&P 500. Comparatively, Palvella Therapeutics has a beta of -0.25, suggesting that its stock price is 125% less volatile than the S&P 500.

Profitability

This table compares Insmed and Palvella Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Insmed	-76.94%	-123.94%	-44.30%
Palvella Therapeutics	N/A	-47.84%	-38.33%

Analyst Ratings

This is a summary of recent ratings and target prices for Insmed and Palvella Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insmed	1	0	22	2	3.00
Palvella Therapeutics	1	0	12	2	3.00

Insmed currently has a consensus target price of $205.52, indicating a potential upside of 58.88%. Palvella Therapeutics has a consensus target price of $209.14, indicating a potential upside of 37.97%. Given Insmed’s higher possible upside, research analysts clearly believe Insmed is more favorable than Palvella Therapeutics.

Institutional & Insider Ownership

40.1% of Palvella Therapeutics shares are held by institutional investors. 2.1% of Insmed shares are held by insiders. Comparatively, 17.2% of Palvella Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Palvella Therapeutics beats Insmed on 7 of the 13 factors compared between the two stocks.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed’s earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

About Palvella Therapeutics

Palvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa.